Suppr超能文献

活体肝移植伴增强静脉流出和脾切除术:小左外叶供肝的理想选择。

Living Donor Liver Transplantation With Augmented Venous Outflow and Splenectomy: A Promised Land for Small Left Lobe Grafts.

机构信息

Transplant Center, Cleveland Clinic, Cleveland, OH.

Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.

出版信息

Ann Surg. 2022 Nov 1;276(5):838-845. doi: 10.1097/SLA.0000000000005630. Epub 2022 Jul 27.

Abstract

OBJECTIVE

Living donor liver transplantation (LDLT) using small grafts, especially left lobe grafts (H1234-MHV) (LLG), continues to be a challenge due to small-for-size syndrome (SFSS). We herein demonstrate that with surgical modifications, outcomes with small grafts can be improved.

METHODS

Between 2012 and 2020, we performed 130 adult LDLT using 61 (47%) LLG (H1234-MHV) in a single Enterprise. The median graft-to-recipient weight ratio was 0.84%, with graft-to-recipient weight ratio <0.7% accounting for 22%. Splenectomy was performed in 72 (56%) patients for inflow modulation before (n=50) or after (n=22) graft reperfusion. In LLG-LDLT, venous outflow was achieved using all three recipient hepatic veins. In right lobe graft (H5678) (RLG)-LDLT, the augmented graft right hepatic vein was anastomosed to the recipient's cava with a large cavotomy. Outcome measures include SFSS, early allograft dysfunction (EAD), and survival.

RESULTS

Graft survival rates at 1, 3, and 5 years were 94%, 90%, and 83%, respectively, with no differences between LLG (H1234-MHV) and RLG (H5678). Splenectomy significantly reduced portal flow without increasing the complication rate. Despite the aggressive use of small grafts, SFSS and EAD developed in only 1 (0.8%) and 18 (13.8%) patients, respectively. Multivariable logistic regression revealed model for end-stage liver disease score and LLG (H1234-MHV) as independent risk factors for EAD and splenectomy as a protective factor (odds ratio: 0.09; P =0.03). For LLG (H1234-MHV)-LDLT, patients who underwent prereperfusion splenectomy tended to have better 1-year graft survival than those receiving postreperfusion splenectomy.

CONCLUSIONS

LLG (H1234-MHV) are feasible in adult LDLT with excellent outcomes comparable to RLG (H5678). Venous outflow augmentation and splenectomy help lower the threshold of using small-for-size grafts without compromising graft survival.

摘要

目的

由于小肝综合征(SFSS)的存在,使用小移植物(尤其是左外叶移植物[H1234-MHV])进行活体肝移植(LDLT)仍然是一个挑战。在此,我们证明通过手术改良,可以改善小移植物的效果。

方法

2012 年至 2020 年,我们在一个单一的企业中进行了 130 例成人 LDLT,其中 61 例(47%)使用了小移植物(H1234-MHV)(LLG)。供肝与受体体重比中位数为 0.84%,供肝与受体体重比<0.7%占 22%。72 例(56%)患者在移植再灌注前(n=50)或后(n=22)进行脾切除术以调节流入。在小左外叶移植物(H1234-MHV)-LDLT 中,使用三个受体肝静脉实现静脉流出。在右外叶移植物(H5678)(RLG)-LDLT 中,增大的供肝右静脉与受体腔静脉用大腔静脉切开术吻合。观察指标包括 SFSS、早期移植物功能障碍(EAD)和存活率。

结果

肝移植物 1、3 和 5 年的存活率分别为 94%、90%和 83%,小移植物(H1234-MHV)与 RLG(H5678)之间无差异。脾切除术可显著减少门静脉流量,而不会增加并发症发生率。尽管大量使用小移植物,但只有 1 例(0.8%)和 18 例(13.8%)患者出现 SFSS 和 EAD。多变量逻辑回归显示,终末期肝病模型评分和小移植物(H1234-MHV)是 EAD 的独立危险因素,脾切除术是保护因素(比值比:0.09;P=0.03)。对于小左外叶移植物(H1234-MHV)-LDLT,与接受再灌注后脾切除术的患者相比,接受再灌注前脾切除术的患者 1 年肝移植物存活率更高。

结论

成人 LDLT 中可以使用小左外叶移植物(H1234-MHV),其结果与 RLG(H5678)相当。静脉流出增加和脾切除术有助于降低使用小供肝的阈值,而不影响肝移植物的存活率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验